-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150

Benzinga·10/12/2026 17:38:37
Listen to the news
BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $164 to $150.